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Abstract
The specificity of Watson–Crick base pairing and the development of several
chemical modifications to oligonucleotides have enabled the development of
novel drug classes for the treatment of different human diseases. This review
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focuses on promising results of recent preclinical or clinical studies on targeting
HDL metabolism and function by antisense oligonucleotides and miRNA-based
therapies. Although many hurdles regarding basic mechanism of action, deliv-
ery, specificity, and toxicity need to be overcome, promising results from recent
clinical trials and recent approval of these types of therapy to treat dyslipidemia
suggest that the treatment of HDL dysfunction will benefit from these unique
clinical opportunities. Moreover, an overview of monoclonal antibodies (mAbs)
developed for the treatment of dyslipidemia and cardiovascular disease and
currently being tested in clinical studies is provided. Initial studies have shown
that these compounds are generally safe and well tolerated, but ongoing large
clinical studies will assess their long-term safety and efficacy.
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1 Antisense Oligonucleotides
Milestone discoveries of the specificity of Watson–Crick base pairing and of RNA
interference and the importance of different RNAs in the genomic regulation of
living organisms have led to the emergence of different RNA-based therapeutics
that hold the promise for the silencing of “drug-able” targets. Although several
classes of RNA-derived therapeutics have reached clinical trials, many hurdles and
challenges have reduced the number of RNA drugs that reach the market. The
recent approvals of an antisense oligonucleotide (mipomersen) by FDA and a gene
therapy (Glybera) by EMA, as well as several ongoing clinical trials, envision to
this type of therapeutics with real future successes. Antisense oligonucleotides
(ASOs), ribozymes, aptamers, miRNAs, and siRNAs are only some examples of
the wide range of RNA-based therapeutics.
1.1 Making Sense of Antisense
The concept underlying antisense technology is simple and straightforward.
Making it simple, during the first step of protein synthesis, DNA is transcribed
into the complementary sequence of a messenger RNA (mRNA) molecule. The
sequences of these “sense” molecules are translated into amino acids to form
proteins. The use of an oligonucleotide sequence tailored complementary, by
virtue of Watson–Crick base pair formation—an “antisense” strand—recognizes
the specific sequence on the mRNA strand, thus preventing it from being translated
into a protein and blocking the function of a gene, as it was first shown by Paul
C. Zamecnik (Zamecnik and Stephenson 1978). This conceptually simple approach
has given rise to a wide variety of oligonucleotide chemistries, and a new class of
therapeutic compounds called antisense drugs continues to expand.
A milestone in this therapeutic arena was the FDA approval of fomivirsen
(marked as Vitravene) as the first antisense oligonucleotide-based therapeutic for
the treatment of a human disease in 1998, namely, for the treatment for cytomega-
lovirus retinitis. After numerous clinical trials of therapeutic oligonucleotides
against several types of diseases (Sehgal et al. 2013), it was not until 2013
(15 years later) that the FDA approved the second antisense oligonucleotide-
based therapeutic, mipomersen (marked as Kynamro), for the treatment of homo-
zygous familial hypercholesterolemia by the inhibition of apolipoprotein B.
ASOs, both RNA and DNA molecules, are unstable in vivo due to the large
amount of nucleases in plasma or cells. Moreover, problems of immune activation
delivery, specificity, and other hurdles have delayed the jump from clinical trials to
the market. For this, significant effort has been expanded to develop nuclease-
resistant oligonucleotides with reduced immunogenicity as well as improved phar-
macokinetic and pharmacodynamic properties. Many chemical modifications
(Fig. 1) have been successfully developed to overcome all these hurdles.
One of the earliest chemical modification for therapeutic oligonucleotides was
the phosphorothioate backbone modification (Marcus-Sekura et al. 1987; Campbell
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et al. 1990). The replacement of the nonbridging oxygens by sulfur dramatically
changed the biological properties of the oligonucleotide, making them excellent
candidates for antisense application: The modified oligonucleotides display
increased resistance to nucleolytic degradation, increased affinity for plasma
proteins, and thus reduced clearance. They are also highly soluble and elicit
RNase H activity which mediate the cleavage of the target mRNA (Bennett and
Swayze 2010).
Sugar modification—mostly chemical substitution at the 20hydroxyl group—has
conferred better drug-like properties to these molecules and have differentiated the
various therapeutic strategies followed by pharmaceutical companies. 20–O-meth-
ylation (20-OMe) enhances both binding affinity and nuclease resistance, but
reduces off-target effects (Yoo et al. 2004; Prakash et al. 2005). 20-fluoro (20-F)
modification also increases the binding affinity for the target driven by the electro-
negative substituent at this position (Monia et al. 1993; Bennett and Swayze 2010).
The 20O-methoxyethyl (20-MOE) modification increases binding affinity and resis-
tance to nucleases as well (Geary et al. 2001; Yu et al. 2004). These kinds of
modifications allow the oligonucleotides to adopt the most energy-favorable con-
formation, thus improving their pharmacological properties, and have enabled
Fig. 1 Examples of chemical modifications used in antisense oligonucleotides and miRNA
therapy
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several MOE-modified drugs to enter clinical trials (Bennett and Swayze 2010).
Another revolutionary sugar modification is the locked nucleic acids (LNA). In the
LNA, the ribose moiety is modified with an extra bridge connecting the 20 oxygen
and 40 carbon (Fig. 1) (Kumar et al. 1998). The bridge “locks” the ribose in the
30-endo (Northern) conformation of sugar, which is often found in the A-form
duplexes. This chemical characteristic increases hybridization, potency, and nucle-
ase resistance but also toxicity in some cases (Swayze et al. 2007). Several
LNA-modified drugs have also entered clinical trials (Sehgal et al. 2013). Several
other chemical modifications to the sugar moiety have been reported in the litera-
ture; however not much of them are on clinical trials yet.
An alternative interesting strategy that improves the cellular uptake, in vivo
stability, and pharmacokinetic properties is the conjugation of the oligonucleotides
to different ligands, for example, to certain types of cell-permeable/penetrating
peptides (Oehlke et al. 2002) or carbohydrates (Zatsepin and Oretskaya 2004).
Moreover several other conjugation methods have been experimentally developed
including nanostructures, liposomes, bile acid, flavin, poly(ethylene glycol), and
others (Karinaga et al. 2006; Singh et al. 2010; Gonzalez-Carmona et al. 2013).
However, for most of them, several challenges remain to be addressed before their
preclinical and clinical development (Lee et al. 2013a, b). Cholesterol conjugation
of oligonucleotides has been reported to work for multiple antisense mechanisms.
Cholesterol conjugation enhances the cellular uptake, particularly hepatic, and
increases in vivo stability (Holasova et al. 2005; Krutzfeldt et al. 2005, 2007).
Even when it is not free of unwanted side effects, as many other antisense
chemistries, cholesterol conjugation is a promising strategy to develop drug
therapies.
1.2 Therapeutic Antisense Oligonucleotides to Treat
Dyslipidemia
After less than 7 years of clinical trials (Kastelein et al. 2006; Raal et al. 2010), the
first antisense oligonucleotide to treat dyslipidemia reached the market in 2013.
Mipomersen sodium (marketed as Kynamro™; ISIS Pharmaceutical) is an ASO
inhibitor of apolipoprotein B-100 synthesis. It is indicated as an adjunct to lipid-
lowering medications to reduce LDL cholesterol, apolipoprotein B (apoB), total
cholesterol, and non-HDL cholesterol in patients with homozygous familial hyper-
cholesterolemia. Other antisense therapies for the treatment of dyslipidemia are
in clinical or preclinical studies, namely, the antisense drug to reduce apoli-
poprotein C-III (ISIS-APOCIIIRx) (Graham et al. 2013), intended to lower tri-
glyceride production in patients with familial chylomicronemia or severe high
hypertriglyceridemia, the antisense drug to reduce apolipoprotein(a) LP(a) in
the liver (ISIS-APO(a)Rx) or the antisense drug to reduce angiopoietin-like 3 pro-
tein (ISIS-ANGPTL3Rx). An ASO against the hepatic microsomal triglyceride
transfer protein (MTP) has also been evaluated, but even when it consistently
reduced the hepatic VLDL/triglyceride secretion, it led to hepatic triglyceride
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accumulation and biomarkers of hepatotoxicity relative to apoB ASO, due in part to
enhanced expression of peroxisome proliferator activated receptor γ target genes
and the inability to reduce hepatic fatty acid synthesis (Lee et al. 2013a).
Thanks to genetic studies, mutations in the proprotein convertase subtilisin/
kexin type 9 (PCSK9) were originally found to cause autosomal dominant hyper-
cholesterolemia (Abifadel et al. 2003), which was further validated by loss-of-
function mutations (Cohen et al. 2005) that lead to reduced cholesterol levels and
reduced coronary heart disease (Cohen et al. 2006). PCSK9 encodes NARC-1
(neural apoptosis-regulated convertase), a human subtilase that is highly expressed
in the liver and the intestine and circulates in plasma. PCSK9 binds to the LDL
receptor and promotes its degradation in the endosomal/lysosomal pathway,
thereby reducing LDL uptake from the circulation and increasing plasma choles-
terol levels. After the premature Phase I trial termination of the PCSK9 phosphor-
othioate LNA RNase H antisense inhibitor SPC5001 (Santaris Pharma) and the
phosphorothioate 20 MOE RNase H PCSK9 antisense inhibitor (BMS-844421;
BMS/ISIS), probably due to side effects (van Poelgeest et al. 2013), only
ALN-PCS siRNA (Alnylam Pharmaceutical) entered Phase II clinical studies to
target PCSK9 for the treatment of hypercholesterolemia. However, this strategy
competes with monoclonal antibodies against PCSK9 that have already entered
Phase III clinical trials (see below).
1.3 Therapeutic Antisense Oligonucleotides for the Increase
of HDL-Cholesterol Levels and Improvement of HDL Function
HDL-cholesterol levels and function can be modified directly or indirectly by
several pathways, some of which have been targeted by ASOs.
1.3.1 Cholesteryl Ester Transfer Protein
One of the first ASO experimentally approached to target HDL levels was directed
against CETP. Sugano’s lab first demonstrated that a single injection of the ASO,
coupled with the complex asialoglycoprotein-poly-L-lysine, into cholesterol-fed
rabbits, reduced CETP activity and increased plasma HDL-cholesterol levels
(Sugano and Makino 1996). This effect was due to reduced liver CETP mRNA
levels, which was accompanied by a reduction in LDL- and/or VLDL-cholesterol
levels. In a longer study, 8-week treatment with the same molecule (30 μg/kg twice
a week) reduced both CETP mass and atherosclerosis in cholesterol-fed rabbits
(Sugano et al. 1998). While triglyceride levels did not change, LDL- and VLDL-
cholesterol levels were significantly decreased by the ASO treatment (Sugano
et al. 1998). Despite these promising preclinical antiatherogenic findings, the
controversial clinical development of CETP inhibitors (Barter et al. 2007; Schaefer
2013) increased the caution for the future development of this type of therapy. In
this context, recent preliminary finding suggests that inhibition of CETP by ASOs
may differ from CETP inhibition by small-molecule inhibitors (Bell et al. 2013).
Indeed, the 20-mer phosphorothioate ASO containing 20-O-methoxyethyl (20MOE)
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targeted to human CETP (ISIS Pharmaceutical) did not only reduce CETP activity
and increase HDL-C levels but also enhance macrophage reverse cholesterol
transport and reduce the accumulation of aortic cholesterol in a CETP transgenic
LDLR/ mice (Bell et al. 2013). This finding together with a previous study
regarding the lack of association of genetic inhibition of CETP (Johannsen
et al. 2012) and possible side effects previously reported for torcetrapib suggests
that not all inhibitors of CETP are equal. Thus inhibition of CETP still holds
promise as a beneficial therapeutic target, but as for other drugs, this needs to be
experimentally and clinically validated.
1.3.2 Endothelial Lipase
Endothelial lipase plays an important role in HDL metabolism (Kuusi et al. 1980;
Voight et al. 2012), and it has been suggested that its inhibition may improve
cardioprotection (Singaraja et al. 2013). In a preliminary study, a 20-mer ASO
containing 20-O-(methoxy)-ethyl (20MOE) modifications on the first five and last
five bases (ISIS Pharmaceutical) to target the rabbit endothelial lipase was tested
in rabbits for 6 weeks (Zhang et al. 2012b). Even though the experimental protocol
did not show a clear increase in HDL-cholesterol levels, the cholesterol content of
large HDL (>12.1 nm) was increased (Zhang et al. 2012b). Whether other ASO
chemistries may increase the impact on HDL-C levels and function is not known,
but this deserves further investigation.
1.3.3 ACAT2
The sterol O-acyltransferase 2, encoded by the SOAT2 gene and originally named
ACAT2 (referred here as ACAT2), is a membrane-bound enzyme, with an acyl-
CoA cholesterol acyltransferase activity, localized in the endoplasmic reticulum.
SOAT2/ACAT2 catalyzes the synthesis of cholesteryl esters from long-chain fatty
acyl-CoA and cholesterol and is involved in cholesterol absorption and the secre-
tion of cholesteryl esters into apoB-containing lipoproteins. ACAT2 is expressed
exclusively in lipoprotein-producing cells, the enterocytes and hepatocytes
(Anderson et al. 1998). While both hepatic and intestinal deletion of ACAT2
improves atherogenic hyperlipidemia and limits hepatic cholesteryl ester accumu-
lation (Zhang et al. 2012a), it has been proposed that specific tissue ACAT inhibi-
tion would be beneficial for atheroprotection (Nissen et al. 2006; Brown
et al. 2008). However, ACAT inhibition is not free of controversies in clinical
development (Nissen et al. 2006). A 20-mer antisense phosphorothioate oligonu-
cleotide containing 2-0-methoxyethyl groups at positions 1–5 and 15–20 was
originally found to reduce hepatic ACAT2 levels and mediate protection against
diet-induced hypercholesterolemia and aortic cholesteryl ester deposition (Bell
et al. 2006). Interestingly, in mice this antisense oligonucleotide (ISIS Pharmaceu-
tical) therapy (25 mg/kg biweekly for 8 weeks) promoted fecal neutral sterol
excretion without altering biliary sterol secretion (Brown et al. 2008). This poten-
tially important finding indicates that the antisense oligonucleotide promotes
non-biliary fecal sterol loss and thus reverses cholesterol transport enhancement.
Pharmacological inhibition of liver ACAT2 by using ASOs has also been shown to
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reduce cholesterol-associated hepatic steatosis (Alger et al. 2010) which may
explain the hypertriglyceridemia observed in mice lacking ACAT2, probably by
enhancing hepatic TG mobilization. In overall, ASO treatment against hepatic
ACAT2 has uncovered other novel benefits distinct from that of HDL function
and increased its therapeutic potential.
Although we are expecting the results of several ongoing clinical trials with
ASOs for different pathologies (Sehgal et al. 2013), the recent approval for com-
mercialization of Kynamro will really increase our interest to follow this therapeu-
tic arena. Even when the long-term toxicity effects and other forms of delivery need
to be evaluated, the promising preclinical results on ASOs to treat HDL levels and
function make them an interesting alternative to small-molecule inhibitors. After
all, opening new possible avenues to treat HDL dysfunction using ASOs makes
more sense than simply awaiting for the discovery of potential small-molecule
inhibitors.
2 miRNAs
Mature microRNAs (miRNAs) are single-stranded, ~21–23 nucleotide (nt) long,
and noncoding RNAs that directly bind, via Watson–Crick base pairing, to
sequences commonly located within the 30untranslated region (30-UTR) of target
mRNAs. This interaction inhibits the translation and/or degradation of mRNAs
(Guo et al. 2010; Krol et al. 2010). However, certain miRNAs can interact with
other target mRNA regions including the 50UTR, coding region, or intron–exon
junction and even increase rather than decrease target mRNA expression
(Vasudevan et al. 2007; Orom et al. 2008; Tay et al. 2008; Schnall-Levin
et al. 2010). RNA sequencing studies have identified ~2,000 miRNAs in our
human genome which are predicted to regulate ~ a third of our genes. The binding
of the “seed” sequence (nucleotides 2–8 at the 50 end of the mature miRNA) is
critical for target selection (Bartel 2009). However, other regions of the miRNA can
bind to the target mRNA and, therefore, almost 60 % of seed interactions are
noncanonical (Helwak et al. 2013). Many miRNAs are evolutionary conserved
among different species. While some of them are ubiquitously expressed, certain
miRNAs are highly expressed or even restricted (Lagos-Quintana et al. 2002; Small
and Olson 2011) to certain cell types and can only target their mRNA target if they
are co-expressed in the same tissue at the same time.
Based on short sequences (“seed”), computational methods and previous valida-
tion studies have revealed that a single miRNA can target hundreds of genes with
either multiple related or different functions in different physiological/pathological
processes or tissues. Likewise, a single mRNA may have different miRNA binding
sites, allowing a coordinated regulation by different miRNAs. While the primary
role of miRNAs seems to be the “fine-tuning” of gene expression (Flynt and Lai
2008), the appearance of this complex RNA-based regulatory network suggests that
miRNAs have probably evolved as buffers against deleterious variation in gene-
expression programs. Even when a single miRNA exerts modest effects on many
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target mRNAs, the additive effect of coordinated regulation of a large suite of
transcripts that govern the same biological process is believed to result in strong
phenotypic outputs (Mendell and Olson 2012). These basic principles of miRNA
mode of function are the basis for a novel and revolutionary type of therapeutics,
called the miRNA-based therapy. However, as the devil is in the details, the high
redundancy among related and non-related miRNAs in the regulation of gene
expression described above reduces the importance of a particular miRNA under
conditions of normal cellular homeostasis. Nevertheless, since under conditions of
stress, the function of miRNAs becomes especially pronounced (Mendell and Olson
2012), the modulation of miRNA function may represent a real alternative to the
conventional one-target drug therapy. However, many hurdles need to be overcome
as other novel players have entered the equation, including pseudo genes (Poliseno
et al. 2010), long noncoding RNAs (lncRNAs) (Cesana et al. 2011), and circular
RNAs (circRNAs) that contain miRNA binding sites. As competing endogenous
RNAs (ceRNAs), they may sequester miRNAs and prevent them from binding to
their mRNA targets (Salmena et al. 2011).
2.1 miRNA-Based Therapy
miRNAs as potential therapeutics have received special attention from the scientific
and clinical audience primarily because of their “promiscuous” mode of action and
the multifactorial nature of most modern metabolic diseases. Moreover, previous
antisense technology and gene therapy approaches, some of them already in market,
have catalyzed the efforts to develop therapies to modulate miRNA levels in vivo.
Although certain questions regarding their biological function, regulation, and
delivery still remain to be answered, the simultaneous modulation of different
components of a complex disease pathway by an miRNA offers a unique and
alternative opportunity to treat disease in a manner that is completely different
from our conventional classical one-target-directed drugs. Eventually this feature
may also enable to bypass tissue insensitivity or drug resistance, characterizing
classical one-target-directed drugs.
Different pharmacological tools have been developed to target miRNA
pathways (van Rooij et al. 2008, 2012; van Rooij and Olson 2012) (Fig. 2). As
miRNAs are generally inhibitors of gene expression, the use of therapies to increase
or block gene expression will result in a decreased or derepression of their mRNA
targets, respectively. Based on these opposite approaches we can classify the
therapeutic application of miRNAs into two strategies. The first strategy involves
an miRNA “gain of function” phenotype, also called “inhibitors,” and aims to
inhibit the function of miRNAs. Several approaches can be utilized for this purpose,
including (1) small-molecule inhibitors directed to regulate miRNA expression,
(2) miRNA masking due to molecules complementary to the 30-UTR of the target
miRNA, resulting in competitive inhibition of the downstream target effects,
(3) miRNA sponges that utilize oligonucleotide constructs with multiple comple-
mentary miRNA binding sites to the target miRNA, and (4) antisense
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oligonucleotides, also known as miRNA antagonists or inhibitors, such as anti-
miRs, locked nucleic acids (LNA), or antagomiRs that by complementarity bind to
miRNAs inducing either duplex formation or miRNA degradation (Davalos and
Suarez 2013). The second strategy involves an miRNA “loss-of-function”
Fig. 2 miRNA-based therapy. Endogenous miRNAs bind to a complementary sequence generally
localized within the 30UTR of target genes and repress the synthesis of the corresponding protein
or degrade the mRNA target. For miRNA replacement therapy, an exogenous miRNA mimic is
delivered systemically to exert a repression of their target genes. Small-molecule activators of
miRNA expression can also be used for this purpose. For endogenous miRNA inhibition, and thus
derepression of their target genes, several approaches can be used. Small-molecule inhibitors can
be directed to repress an miRNA expression. miRNA masking employs molecules complementary
to the 30-UTR of the target miRNA, resulting in competitive inhibition of the downstream target
effects. miRNA sponges use oligonucleotide constructs with multiple complementary miRNA
binding sites to the target miRNA, thereby preventing them from binding to their target mRNAs.
Antisense oligonucleotides, also known as miRNA antagonists, inhibitors, or anti-miRs, comple-
mentary bind to a target miRNA inducing either duplex formation or miRNA degradation. Novel
approaches can arise from recent discovery of other noncoding RNAs that regulate miRNA
activity. That is, circular RNAs can sequester a large amount of miRNAs acting as competitive
inhibitors for miRNA binding, thereby preventing the mRNA repression of the target miRNA. PA
protocatechuic acid, DHA docosahexaenoic acid
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phenotype, also called “mimic,” and aims to enhance the function of miRNAs. The
approaches that can be utilized for this strategy include (1) small-molecule
activators or inductors of miRNA expression and (2) miRNA mimics, which as
exogenous miRNAs aim to repress the function of their mRNA targets. They are
also called “miRNA replacement therapy.”
2.1.1 Therapeutic miRNA Mimics or miRNA Replacement Therapy
In principle, delivery of miRNA mimics as pharmacological therapy could be used
in situations in which a reduction in miRNA levels is responsible for the develop-
ment of a pathological state, such as those produced in the human rare Mendelian
disorders or certain types of cancer, where regions containing miRNAs are deleted
(Calin et al. 2002). Genetic mutation in either miRNA seed region or other miRNA
regions that results in a reduced functional miRNA with a significant reduction of
mRNA targeting required for normal function (Mencia et al. 2009; Ryan
et al. 2010) could also benefit from these therapies. The use of miRNA mimics
for therapy has been really challenging and their development has been catalyzed
by gene therapy. Gene therapy was first conceptualized in 1972 (Friedmann and
Roblin 1972) as an approach to deliver a gene or alter the expression of a gene in
order to replace a mutated gene or deliver a therapeutic functional gene using a
vector to treat a disease. Since then, the FDA has approved hundreds of clinical
trials during the last 20 years using different approaches, for different diseases, with
some promising results. However, it was not until 2012 that the European
Medicines Agency (EMA) has approved the first gene therapy drug, alipogene
tiparvovec (marked as Glybera)—for the treatment for lipoprotein lipase defi-
ciency—and the first of its kind in the western society. It uses a viral vector, the
adeno-associated virus serotype 1 (AAV1), to deliver a copy of the human lipopro-
tein lipase gene. As proof of concept, many preclinical data generated in animal
models suggest that pharmacological delivery of miRNA mimics is feasible and
current strategies to deliver miRNA mimics are promising. Indeed, a synthetic
version of miR-34a (MRX34, Mirna Therapeutics), delivered using a liposomal
delivery formulation, was the first miRNA to advance into a human Phase 1 clinical
trial for cancer (clinicaltrials.gov number NCT01829971).
Different experimental strategies to deliver miRNA mimics have been tested.
Synthetic miRNA or pre-miRNA duplexes, normally modified for better stability
and cellular uptake, have been incorporated into different delivery systems, includ-
ing lipid nanoparticles with surface receptor ligands or other components to
increase tissue/cell specificity (Wiggins et al. 2010; Trang et al. 2011; Piao
et al. 2012). Adeno-associated viruses (AAV) (Miyazaki et al. 2012) are another
interesting alternative. Certain tissue specificity due to the natural tropism of
different AAV serotypes (Zincarelli et al. 2008) could be achieved. Viral-based
vectors, including adenoviruses and lentiviruses (Chistiakov et al. 2012; Langlois
et al. 2012), consist another well-studied delivery method.
There are still questions regarding the biological function of miRNAs, particu-
larly those related to extracellular miRNAs, intercellular communication by
miRNAs, and their presence in numerous biological fluids that need to be
addressed. As miRNAs can circulate in the blood or different biological fluids in
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microvesicles, exosomes, Ago2-containing complexes, or HDL (Arroyo et al. 2011;
Vickers et al. 2011; Chen et al. 2012), opportunities will probably arise for
therapeutically exploiting the physiologic forms of miRNA delivery (Davalos and
Fernandez-Hernando 2013). The basic function of miRNAs, which is to target
different mRNAs of different biological pathways, raises the possibility of unin-
tended off-target effects (van Rooij et al. 2008). Several hurdles need to be solved
including the delivery issues, as uptake of a miRNA by tissues that normally do not
express them will result in the repression of their targets that could ultimately cause
side effects. Moreover, the overexpression of a particular miRNA, even in its
specific target cell, could modify either its own secretion or the secretion of other
miRNAs that could target a different cell/tissue type causing unwanted side effects.
2.1.2 Therapeutic miRNA Inhibition or Anti-miR Therapy
In contrast to miRNA replacement therapy, miRNA inhibitors as therapy have
benefits compared to existing antisense technology in the market. Over the last
decade, several miRNAs have been characterized, and it was found that their
induction or overexpression plays a causal role in a disease or directly contributes
to it. Thus, pharmacological inhibition of miRNA activity in vivo has been
achieved through the use of different chemically modified single-stranded reverse
complement oligonucleotides known as antisense oligonucleotide (Fig. 1). Anti-
sense oligonucleotides (ASOs) complementary to the mature miRNA sequence,
“antagomiRs,” were the first miRNA inhibitors in mammals (Krutzfeldt
et al. 2005). Since then different chemical modifications were performed to ASOs
in order to modify their pharmacological, pharmacokinetic, and pharmacodynamic
properties: cholesterol, conjugated via a 20-O-methyl (20-O-Me) linkage in the
30end, to increase cellular uptake and stability; phosphorothioate linkage to increase
stability and reduce clearance by promoting plasma protein binding; 20-O-methyl
(20-O-methyl)-modified ribose sugar to protect from endonuclease activity
(Krutzfeldt et al. 2005, 2007); 20,40-constrained 20-O-ethyl(cET)-modified
nucleotides to improve potency and stability (Seth et al. 2010; Pallan et al. 2012);
20-O-methoxyethyl (20-MOE) and 20-fluoro (20-F) modifications to improve in vivo
efficacy (Davis et al. 2009); and the 20-fluoro/methoxyethyl (20-F/MOE) modified
with phosphorothioate backbone-modified anti-miR technology which has been
shown to be efficacious in nonhuman primates (Rayner et al. 2011a). Lastly, locked
nucleic acid (LNA) gives promising properties in order to be used as miRNA
therapy. As LNA anti-miR has high-binding affinity and increased selectivity to
complementary RNA, the sequence length can be reduced. LNA also increases the
duplex’s melting temperature and stability in biological systems (Vester and
Wengel 2004; Elmen et al. 2005; Veedu and Wengel 2010). In preclinical studies
LNA-modified anti-miR technology has been widely shown to be efficacious in
nonhuman primates (Elmen et al. 2008; Lanford et al. 2010). Moreover, it was the
first anti-miR therapy to show efficacy in human trials (clinicaltrials.gov number
NCT01200420) (Janssen et al. 2013). A phosphorothioate backbone tiny 8-mer
LNA-modified anti-miRs for in vivo use (Obad et al. 2011) has also been developed
particularly for reducing the activity of entire miRNA families that share a common
seed region.
660 A. Da´valos and A. Chroni
For now, anti-miR therapy is administered parenterally. Although miRNA
inhibitors are generally water soluble, their size and charge prevent them to be
absorbed by the intestine, thus becoming bad candidates for oral therapy. Their
long-lasting effects shown in different studies (Krutzfeldt et al. 2005; Elmen
et al. 2008; Lanford et al. 2010; Obad et al. 2011; Rayner et al. 2011a, b; van
Rooij and Olson 2012) suggest their potential use for chronic rather than acute
disease. Whereas under normal unstressed conditions miRNAs only slightly change
protein expression (Selbach et al. 2008), pharmacological inhibition under patho-
logical stress conditions may become relevant (Mendell and Olson 2012). Even
when specific toxicity associated with the inhibition of a particular miRNA has not
been clearly reported, as for other LNA-containing ASO therapies, they might not
be free of potential off-target effects (Swayze et al. 2007). Thus, their evaluation
might be challenging and should be done in long-lasting studies. Moreover, other
miRNAs and mRNAs (independent of miRNA mediated) modified by the stress
conditions and other regulatory mechanism exerted by ceRNA, lncRNAs, and
circRNAs will greatly influence the pharmacodynamics of every particular anti-
miR chemistry.
Although there are many aspects of anti-miR biology that need to be addressed,
this therapeutic approach successfully led up to the first miRNA-based clinical
trials for the treatment of hepatitis C virus infection by targeting miR-122 with an
LNA-anti-miR (miravirsen or SPC3649; Santaris Pharma, Denmark) with very
promising results (Janssen et al. 2013). Thus, the biological interest in controlling
miRNAs level therapeutically anticipates the further development of this new class
of drugs.
2.2 Micromanaging Cholesterol Efflux, RCT, HDL Levels, and HDL
Function
Several miRNAs have been investigated for their potential use as therapeutics for
different aspects of HDL function. Although still in preclinical studies, the phar-
macological inhibition of the miRNA-33a/b is leading this aspect of research. These
and other miRNAs directly or indirectly related to cellular cholesterol efflux, RCT,
and HDL function that could potentially be used as pharmacological therapy will be
discussed below.
2.2.1 miR-33a/b
The genomic localization of this family of miRNAs within the introns of the master
regulators of lipid and cholesterol metabolism, the SREBPs-, has catalyzed the
discovery of this miRNA as major player in HDL function and cholesterol efflux
(Horton et al. 2002; Horie et al. 2010; Marquart et al. 2010; Najafi-Shoushtari
et al. 2010; Rayner et al. 2010). Modulation of miR-33a/b levels in preclinical
studies resulted in changes in cellular cholesterol efflux (Najafi-Shoushtari
et al. 2010; Rayner et al. 2010; Davalos et al. 2011). In vivo modulation of
miR-33a/b either by target disruption of the gene, LNA anti-miR, or viral delivery
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of sense and antisense oligonucleotides significantly alters circulating HDL-C and
reverse cholesterol transport (Horie et al. 2010; Marquart et al. 2010; Najafi-
Shoushtari et al. 2010; Rayner et al. 2010), which is consistent with the regulation
of its targets ABCA1, ABCG1, and NPC1. miR-33 deficiency reduces the progres-
sion of atherosclerotic plaque (Horie et al. 2012). Likewise the antisense inhibition
of this miRNA for 4 weeks in LDLR/ mice led to the regression of atherosclero-
sis by enhancing Abca1 expression and cholesterol removal in plaque macrophages,
reducing the size and inflammatory gene expression of plaques, and increasing
markers of plaque stability (Rayner et al. 2011b). Even when there is conflicting
results in this aspect (Marquart et al. 2013), there is still therapeutic potential in
inhibiting this miRNA family for atherosclerotic cardiovascular disease. The dra-
matic increase of SREBP1c (host of miR-33b)—in insulin resistance states—which
contributes to both increased levels of plasma triglycerides and low HDL levels
(Brown et al. 2010) also suggests the therapeutic use of anti-miR-33 for metabolic
syndrome. Indeed, as proof of concept, in African green monkeys fed with a high
carbohydrate diet, the inhibition of miR-33b for 12 weeks reduced hepatic expres-
sion of Abca1, increased the function of HDL evaluated as macrophage cholesterol
efflux, raised plasma HDL levels, and reduced VLDL triglyceride levels (Rayner
et al. 2011a).
Thus, the therapeutic potential of anti-miR-33 is not only based on Abca1,
cholesterol efflux, and RCT, but miR-33a/b also controls the expression of impor-
tant genes involved in fatty acid β-oxidation, insulin signaling, lipid metabolism,
and biliary transporters (Allen et al. 2012; Horie et al. 2013) (Gerin et al. 2010;
Davalos et al. 2011; Rayner et al. 2011a, b), including carnitine palmitoyl-
transferase 1A (Cpt1a), the carnitine O-octanoyltransferase (Crot), the mitochon-
drial beta hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA
hydratase (Hadhb), sirtuin 6 (Sirt6), 50-AMP-activated protein kinase catalytic
subunit alpha-1 (PRKAA1 gene, Ampkα), insulin receptor substrate 2 (Irs2),
SREBP-1, and the biliary transporters ABCB11 and ATP8B1. Although specific
toxicity associated to miR-33 inhibition has not been reported, its safety should be
carefully evaluated as other targets related to cell proliferation, cell cycle, and
inflammation, including cyclin-dependent kinase 6 (Cdk6), cyclin D1 (Ccnd1), the
tumor suppressor p53, and the nuclear receptor coregulator receptor interacting
protein 140 (Rip140) have also been described (Herrera-Merchan et al. 2010; Ho
et al. 2011; Cirera-Salinas et al. 2012).
Different anti-miR chemistries were tested for inhibiting miR-33 family
members including LNA-antisense oligonucleotide (Najafi-Shoushtari et al. 2010)
and 20F/MOE-modified phosphorothioate backbone-modified ASO (Rayner
et al. 2011a, b) (Regulus Therapeutics). Interestingly, the miR-33 family has special
structural characteristics, not common in most mammalian miRNAs. They have a
repetitive sequence similar to that of seed (UGCAUUG) between nucleotides
13 and 19 apart from their native seed sequence between nucleotides 2 and 8 at
the 50 end of the mature miRNA. This could be benefited by the use of phosphor-
othioate backbone tiny 8-mer LNA-modified anti-miRs chemistry. Indeed recent
promising results suggest the efficacy and safety of an 8-mer LNA anti-miR against
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miR-33 family during a 108-day treatment in a nonhuman primate metabolic
disease model (Rottiers et al. 2013) (Santaris Pharma). Which anti-miR chemistry
will have the best pharmacologic and safety profile for human use is not known, but
pharmaceutical industries (Santaris Pharma and Regulus Therapeutics) are inten-
sively researching on this topic and anti-miRs will probably soon enter clinical
trials.
2.2.2 miR-758 and miR-106b
Like miR-33a/b, miR-758 and miR-106b target ABCA1. The expression of
miR-758 is somehow mediated by high cholesterol levels and regulates cellular
cholesterol efflux by directly targeting the 30UTR of Abca1. As the relative expres-
sion of miR-758 is particularly elevated in the brain (Ramirez et al. 2011), it seems
that it regulates other important proteins involved in several neurological functions
including SLC38A1, IGF1, NTM, XTXBP1, and EPHA1. Although our under-
standing of the role of miR-758 under physiological and pathological conditions
needs to be enhanced first, the development of appropriate anti-miR chemistries for
targeting the brain miR-758 still remains to be dealt with, including bypassing the
blood–brain barrier and delivery to specific cell types. Also in neuronal cells,
miR-106b was found to directly target the 30UTR of Abca1 as having a perfect
8-mer and several supplementary pairing sites in mammals (Bartel 2009; Kim
et al. 2012). The miR-106b not only reduces cholesterol efflux to apoA-I but also
increases amyloid β (Aβ) peptide secretion and clearance (Kim et al. 2012). The
production and/or aggregation of Aβ peptide is believed to play a central role in the
pathogenesis of Alzheimer disease (AD). While the final effect might be directly
linked to miR-106b effects on Abca1 rather than other target genes in neuronal cells
(Kim et al. 2012), we should not discard other indirect effects as this miRNA also
targets various other proteins related to cell proliferation and differentiation (Brett
et al. 2011). Moreover, the amyloid precursor protein (APP) is also a target of
miR-106b (Hebert et al. 2009). The final phenotype of the inhibition of the neuronal
miR-106b is not known, but in the context of cholesterol efflux in the CNS,
miR-106b could be an interesting target for the regulation of neuronal cholesterol
excess.
2.2.3 miR-26 and miR-144
The nuclear liver X receptors (LXRs) control distinct aspects of cholesterol homeo-
stasis at the transcriptional level including uptake (IDOL) or efflux (ABCA1,
ABCG5, ABCG8). Induction of LXR by using agonists revealed the repression of
the miR-26 and the induction of the miR-144 family. LXR activation increased the
expression of Abca1 and ADP-ribosylation factor-like7 (Arl7), both of which
participate in apoA-I-dependent cholesterol efflux (Engel et al. 2004). The
miR-26-a-1 expression is also regulated by LXR (Sun et al. 2012) and directly
targets the 30UTR of Abca1 and Arl7. Thus the inhibition of this miRNA, in
principle, should enhance cholesterol efflux and RCT as LXR activation does. By
contrast, LXR activation induces the expression of miR-144 (Ramirez et al. 2013).
Interestingly, miR-144 is not only activated by LXR but also by the nuclear receptor
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farnesoid X receptor (FXR) (Vickers and Rader 2013). FXR is highly expressed in
the liver and the intestine. It controls the hepatic sterol and bile acid levels through
transcriptional regulation of lipid-associated and bile acid genes. The miR-144
directly targets the 30UTR of ABCA1, thus reducing ABCA1 protein levels and
cholesterol efflux, but not ABCA1 mRNA in all models tested (de Aguiar Vallim
et al. 2013; Ramirez et al. 2013; Vickers and Rader 2013). In vivo therapeutic
inhibition of miR-144 by using either 20-fluoro/20-methoxyethyl, phosphorothioate
backbone-modified anti-miRs (Regulus Therapeutics) 5 mg/kg biweekly treatments
(intraperitoneal injections) for 4 weeks (de Aguiar Vallim et al. 2013) or mirVana
inhibitors (7 mg/kg) coupled with In vivo fectamine (Invitrogen) for intravenous
injections twice every 3 days (Ramirez et al. 2013) increased both hepatic ABCA1
protein expression and HDL-C levels in mice. It is important to note that the hepatic
effect of miR-144 might differ from that of miR-33a/b (Vickers and Rader 2013).
Activation of FXR will induce both the scavenger receptor B1 (SCARB1) and
miR-144, thereby increasing the uptake of plasma HDL cholesterol and reducing
both ABCA1 protein levels and cholesterol efflux to lipid-poor apoA-I. This would
lead to increased biliary excretion of cholesterol via ABCG5/ABCG8 rather than
resecretion of cholesterol via ABCA1 to preβ-HDL and the formation of HDL
(de Aguiar Vallim et al. 2013). The final therapeutic outcome by modulating
miR-144 levels in vivo and other questions regarding safety issues still need to be
experimentally tested, as other miR-144 targets are directly related to cancer
proliferation (Guo et al. 2013; Zhang et al. 2013).
2.2.4 miR-10b, miR-128-2, miR-145
Several other miRNAs have been described to regulate ABCA1, ABCG1, and other
genes related to cholesterol efflux. In the context of small-molecule activators to
either induce or repress miRNAs expression, polyphenols and fatty acids are
emerging as possible candidates to exert part of their biological effects by this
mechanism (Visioli et al. 2012; Tome-Carneiro et al. 2013). Anthocyanidins are
pigmented polyphenols found in different vegetables, fruits, as well as common
beverages including grape and berry juice and red wine. Protocatechuic acid (PCA)
was found to be an intestinal microbiota metabolite of Cyanidin-3-O-glucoside
(Cy-3-G), a major anthocyanidin. Interestingly the antiatherogenic effect of PCA
was recently found to be mediated through miR-10b (Wang et al. 2012). Indeed,
PCA increases macrophage cholesterol efflux through the repression of miR-10b.
The miR-10b directly represses Abca1 and Abcg1 and negatively regulates choles-
terol efflux from lipid-loaded macrophages (Wang et al. 2012). Although several
genes involved in cancer progression are targets of the oncogenic miR-10b
(Gabriely et al. 2011; Tsukerman et al. 2012), its inhibition by either anti-miR
chemistries or dietary intervention with anthocyanidins may be an interesting
pharmacological approach to increase cholesterol efflux and RCT. The use of
other pharmacological approaches, including small natural dietary compounds, is
still under intense investigation (Visioli and Davalos 2011) and provides an attrac-
tive alternative to the use of ASOs or miRNA mimic technology.
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miR-145 was described as a major regulator of smooth muscle fate by targeting a
network of transcription factors, including Klf4, myocardin, and Elk-1 which
regulate the quiescent versus proliferative phenotype of smooth muscle cells
(Cordes et al. 2009). miR-145 also regulate ABCA1 expression and function. In
pancreatic beta cells, its inhibition improves glucose-stimulated insulin secretion.
Inhibition of miR-145b has been shown to increase ABCA1 expression, promoting
HDL biogenesis in the liver and improving glucose-stimulated insulin secretion in
islets (Kang et al. 2013). The miR-128-2 was described to be frequently
downregulated in breast cancer, and its overexpression impeded several oncogenic
traits of mammary carcinoma cells (Qian et al. 2012). ABCA1, ABCG1, and RXRα
are direct targets of miR-128-2, and its inhibition induces cholesterol efflux
(Adlakha et al. 2013). Although we lack in vivo evidence of their pharmacological
modulation and HDL function, recent evidence of association of cholesterol levels
and cancer (Nelson et al. 2013) warrants further investigation of these miRNAs.
2.2.5 Other miRNA Related to Cholesterol Efflux and Cholesterol
Homeostasis
Several other miRNAs have been described to indirectly regulate different aspects
of cholesterol efflux, RCT, and cholesterol metabolism, but their real physiological
contribution to HDL function is not well understood. Several miRNAs have been
described that regulate different targets in autophagy (Xu et al. 2012), the cell
catabolism process by which unnecessary or dysfunctional cellular components are
degraded through the lysosomal machinery. Lipid droplet cholesteryl ester hydro-
lysis is being recognized as an important step in cholesterol efflux (Ouimet
et al. 2011); thus miRNAs that target key pathways in lipid-loaded macrophage
autophagy and/or cholesterol ester hydrolases might be interesting targets to pro-
mote cholesterol efflux (Davalos and Fernandez-Hernando 2013). Caveolin, the
major protein coat of caveolae, has also been proposed to contribute to cellular
cholesterol efflux (Truong et al. 2010; Kuo et al. 2011). Even when there is
increasing evidence of several miRNAs including miR-103, miR-107, miR-133a,
miR-192, miR-802, and others that target caveolin (Nohata et al. 2011; Trajkovski
et al. 2011), their contribution to cholesterol efflux and RCT remains unknown.
miR-125a and miR-455 were found to repress the lipoprotein-supported steroido-
genesis by targeting SR-BI (Hu et al. 2012). miR-185, miR-96, and miR-223 were
also found to target SR-BI and repress HDL-cholesterol uptake (Wang et al. 2013).
Even though there is lack of evidence for any effect on HDL metabolism and
in vivo pharmacological modulation for any of those miRNAs, the major role of
SR-BI in HDL metabolism warrants further research on this topic.
Although the potential of LNA anti-miR-122-based therapy (Miravirsen,
Santaris Pharma) is fascinating, much more needs to be elucidated about miRNA
biology and miRNA regulatory networks in human diseases before we can intro-
duce such research into clinical care. Moreover, new opportunities for therapeutic
interventions by exploiting the different physiologic forms of miRNA delivery in
biological fluids (associated with microvesicles, exosomes, Ago2-containing
complexes, or HDL particles) will arise. In addition, in the postgenomic and
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“RNA world” era, new types and new roles of noncoding RNAs continue to
emerge, suggesting that there is much yet to be discovered in this therapy arena.
3 Antibodies
The use of monoclonal antibodies (mAbs) for the treatment of various diseases,
including cancers and autoimmune diseases, has been established for at least
15 years. The specificity of mAbs to the target antigen offers clear benefit for
their use over conventional pharmacotherapy. Today mAbs are being developed for
the treatment of dyslipidemia and cardiovascular disease. An overview of
approaches to antibody therapy for the decrease of LDL cholesterol, increase of
HDL cholesterol, treatment of HDL dysfunction, and reduction of cardiovascular
events is provided below. In addition, approaches of active immunization to
modulate atherosclerosis with promising results in preclinical studies are discussed.
3.1 LDL-Cholesterol Lowering Approaches: Proprotein
Convertase Subtilisin/Kexin Type 9 Blocking Antibodies
Statins reduce LDL-cholesterol (LDL-C) levels by increasing the hepatic uptake of
LDL through inhibiting HMG CoA reductase and subsequently cholesterol biosyn-
thesis. A meta-analysis of data from 90,056 participants in 14 randomized trials
showed that statin therapy can safely reduce the 5-year incidence of major coronary
events, coronary revascularization, and stroke by about one fifth per mmol/L
reduction in LDL-C (Baigent et al. 2005). In addition a newer meta-analysis of
data from 170,000 participants in 26 randomized trials of statins showed that each
1 mmol/L LDL-cholesterol reduction reduces the risk of occlusive vascular events
by about a fifth, irrespective of baseline cholesterol concentration, which implies
that a 2–3 mmol/L reduction would reduce risk by about 40–50 % (Baigent
et al. 2010). However, a significant proportion of patients treated with statins fail
to achieve the recommended levels of LDL-C (Catapano 2009). Furthermore, even
when LDL-C is reduced at the recommended levels by statins, there is a residual
50–60 % risk, and therefore, new targets for therapeutic intervention need to be
developed.
Loss-of-function mutations in proprotein convertase subtilisin/kexin type
9 (PCSK9) gene result in low levels of LDL-C and protect against coronary heart
disease. These observations have made PCSK9 one of the most intensively
investigated novel targets to treat hypercholesterolemia (Cohen et al. 2005,
2006). PCSK9, a protein mainly expressed in the liver and intestine, is present in
human plasma (Lambert et al. 2012). PCSK9 binds to LDL receptors (LDLRs) and
thereby targets the internalized receptor to lysosomal degradation and thus limits
recycling of receptor to the plasma membrane for LDL uptake (Zhang et al. 2007).
Statins have been shown to increase PCSK9 expression, an effect that blunts the
LDL-C lowering effectiveness of statins (Mayne et al. 2008). Therefore, the
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inhibition of interaction between PCSK9 and LDLR is expected to increase the
LDLRs that are available in the plasma membrane of hepatocytes and as a conse-
quence reduce plasma LDL-C. In addition, blocking the interactions between
PCSK9 and LDLR may increase the lipid-lowering efficacy of statins.
Various approaches for decreasing PCSK9 levels or blocking PCSK9/LDLR
interactions are being explored. By far the most advanced approach aims to inhibit
PCSK9/LDLR interactions by the use of monoclonal antibodies targeting PCSK9
(Catapano and Papadopoulos 2013; Kramer 2013). Currently, clinical or preclinical
trials for at least 13 different anti-PCSK9 antibodies are being conducted, with two
compounds having entered Phase 3 of clinical development (Catapano and
Papadopoulos 2013; Kramer 2013) (Table 1).
Preclinical studies in rodents and nonhuman primates showed that several anti-
PCSK9 antibodies increased hepatic LDLR protein levels and reduced plasma
LDL-C levels up to 80 % (Chan et al. 2009; Gusarova et al. 2012; Liang
et al. 2012; Chaparro-Riggers et al. 2012; Zhang et al. 2012c; Ni et al. 2011).
Reported results from Phase 1 studies in humans using REGN727/SAR236553
(alirocumab), AMG 145 (evolocumab), and PF-04950615 (RN316, bococizumab)
anti-PCSK9 antibodies showed that the treatments are generally well tolerated and
significantly reduce plasma LDL-C levels in healthy subjects or hypercholes-
terolemic patients, both as monotherapy and when added to statin treatment
(Stein et al. 2012b; Dias et al. 2012; Gumbiner et al. 2012a, b). Phase 2 trial results
have also been reported for alirocumab and evolocumab anti-PCSK9 antibodies.
When alirocumab was administered subcutaneously at doses ranging from 50 to
150 mg every 2 weeks or 200–400 mg every 4 weeks to patients with primary
hypercholesterolemia on top of ongoing stable atorvastatin therapy (10, 20,
40, 80 mg/day), additional reductions in LDL-C, than that accomplished with
atorvastatin alone, were observed (McKenney et al. 2012; Roth et al. 2012). The
reduction of LDL-C levels was found to be similar irrespective of statin dose,
indicating that the coadministration of alirocumab with atorvastatin may provide
benefit to patients that fail to achieve their LDL-C target using high-dose statins or
are intolerant to high-dose statins (McKenney et al. 2012; Roth et al. 2012). Great
reductions in LDL-C levels were also obtained when evolocumab was administered
at doses ranging from 70 to 140 mg every 2 weeks or 280–420 mg every 4 weeks to
patients with hypercholesterolemia, either as a monotherapy or in combination with
a stable dose of statin with or without ezetimibe therapy, or to statin-intolerant
patients due to muscle-related side effects on ezetimibe therapy (Giugliano
et al. 2012; Koren et al. 2012; Sullivan et al. 2012). In other studies of patients
with heterozygous familial hypercholesterolemia and elevated LDL-C on intensive
statin use, with or without ezetimibe therapy, the administration of alirocumab or
evolocumab resulted in substantial further LDL-C reduction (Stein et al. 2012a;
Raal et al. 2012). In addition to their capacity to reduce LDL-C levels, alirocumab
and evolocumab were shown to reduce lipoprotein(α) levels in patients with
hypercholesterolemia receiving statin therapy (McKenney et al. 2012; Desai
et al. 2013) or patients with heterozygous familial hypercholesterolemia on statins,
with or without ezetimibe therapy (Stein et al. 2012a; Raal et al. 2012).
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Alirocumab and evolocumab are currently further tested in 13 and 10 Phase
3 clinical trials, respectively (Table 1), for long-term efficacy and safety, either as
monotherapy or on top of other lipid-modifying therapies and in various patient
populations (e.g., subjects with primary hypercholesterolemia or mixed
dyslipidemia, with high cardiovascular risk and with hyperlipidemia or mixed
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dyslipidemia, with heterozygous familial hypercholesterolemia, with clinically
evident cardiovascular disease, with a 10-year Framingham risk score of 10 % or
less, undergoing coronary catheterization, who recently experienced an acute
coronary syndrome, with statin intolerance). Among these Phase 3 clinical studies,
two studies, which are conducted in numerous study centers across the United
States, Canada, Western and Eastern Europe, South America, Australia, Africa, and
Asia, will assess the effect of candidate drugs on the occurrence of cardiovascular
events for up to 64 months in large-sized patient groups. Specifically, the effect of
alirocumab (ODYSSEY Outcomes, NCT01663402) on the occurrence of cardio-
vascular events (composite endpoint of coronary heart disease (CHD) death, non-
fatal myocardial infarction (MI), fatal and nonfatal ischemic stroke, unstable angina
requiring hospitalization) is evaluated in 18,000 patients who have experienced an
acute coronary syndrome event 4–16 weeks prior to randomization and are treated
with evidence-based medical and dietary management of dyslipidemia (time frame:
up to month 64). Another objective of the study is the evaluation of the effect of
alirocumab on secondary endpoints (any CHD event, major CHD event, any
cardiovascular event, composite of all-cause mortality/nonfatal MI/nonfatal ische-
mic stroke, all-cause mortality), as well as on blood lipids and lipoprotein levels
(time frame: up to month 64). In addition, the long-term safety and tolerability of
alirocumab will be evaluated. In another large clinical trial (FOURIER,
NCT01764633), the effect of evolocumab used in combination with statin therapy
on additional LDL-C reduction and risk of cardiovascular death, MI, hospitalization
for unstable angina, stroke, or coronary revascularization is evaluated in 22,500
patients with clinically evident cardiovascular disease. The primary endpoint is the
time to cardiovascular death, MI, hospitalization for unstable angina, stroke, or
coronary revascularization, whichever occurs first (time frame: 5 years). Another
objective of the study is the evaluation of the effect of evolocumab on secondary
endpoints, such as time to death by any cause, cardiovascular death, hospitalization
for worsening heart failure, ischemic fatal or nonfatal stroke, and transient ischemic
attack, whichever occurs first (time frame: 5 years).
3.2 Approaches to Antibody Therapy for the Increase of HDL-
Cholesterol Levels
Numerous clinical and epidemiological studies have demonstrated an inverse
association between HDL-cholesterol (HDL-C) levels and the risk of cardiovascu-
lar disease (Gordon et al. 1977; Assmann et al. 1996). Furthermore, HDL exerts a
series of antiatherogenic properties (Navab et al. 2011). Thus, raising of HDL-C
levels is expected to translate into a reduction of cardiovascular events and has led
to serious efforts to develop new therapies that can increase the concentration of
HDL-C. Therapeutic strategies using antibody-based blocking of proteins of the
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HDL metabolism pathway that result in increase of HDL-C levels are discussed
below.
3.2.1 Cholesteryl Ester Transfer Protein
Cholesteryl ester transfer protein (CETP) promotes net mass transfer of cholesteryl
esters from HDL to other plasma lipoprotein fractions (Barter and Rye 2012).
Therefore, inhibition of CETP can increase the concentration of HDL-C and
CETP inhibitors have been capable to increase HDL-C levels in preliminary
clinical trials, while clinical outcome trials are ongoing (Barter and Rye 2012;
Landmesser et al. 2012). The properties and effects of different CETP small-
molecule inhibitors that were observed in clinical trials are being described by
Staels et al. in chapter “Emerging Small-Molecule Drugs.”
An alternative approach involves the blocking of CETP action with an antibody,
named CETi-1 (developed by AVANT Immunotherapeutics), raised against a
dimerized synthetic peptide, including residues 461–476 of human CETP and T
cell epitope of tetanus toxoid (residues 830–843), and formulated with aluminum-
containing adjuvants (Davidson et al. 2003). In a Phase II study, CETi-1 was shown
to be safe, and >90 % of treated patients with the highest dose of vaccine showed
1 year after vaccination with CETi-1 an immune response with an increase of
HDL-C by 8 % (Komori 2004). However, this trial failed to meet the primary
endpoint of increasing plasma HDL-C concentrations in the vaccine-treated groups
as compared to the placebo group, due to the low titers of antihuman CETP
antibody achieved in a number of the vaccinated subjects, and CETi-1 is no longer
in development (Komori 2004).
A few years ago, in order to improve the efficacy of the CETi-1 vaccine,
AVANT Immunotherapeutics researchers examined in mice and rabbits the immu-
nogenicity of CETi-1 with the coadministration of the investigational TLR9 agonist
VaxImmuneTM (CPG 7909) as an adjuvant (Thomas et al. 2009). In parallel, they
studied the immunogenicity of another anti-CETP antibody, the PADRE-CETP,
raised against a monomeric peptide, in which a PADRE T cell epitope
(aK-Cha-VAAWTLKAa) replaces the TT(830–843) T cell epitope of CETi-1,
with or without the coadministration of VaxImmuneΤM. The studies showed that
PADRE T cell epitope is more potent than the TT(830–843) epitope in providing
help for the anti-CETP antibody response and that the coadministration of
VaxImmuneΤM with either vaccine increased immunogenicity as measured by
antibody response (Thomas et al. 2009). However, there is no information for the
initiation of clinical trials using these new vaccination approaches up to date.
Another recent CETP vaccination approach involves the ATH-03 anti-CETP anti-
body (developed by Affiris AG), using a small peptide fragment of the CETP
protein acting as a B cell epitope (Kramer 2013), which has entered Phase 1 trials
to assess its safety and immunogenicity (ClinicalTrials.gov Identifier:
NCT01284582).
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3.2.2 Endothelial Lipase
Endothelial lipase (EL) is a phospholipase that participates in HDL metabolism and
regulates HDL-C levels in humans and mice (Yasuda et al. 2010; Annema and
Tietge 2011). Early studies in which EL was inhibited in wild-type, hepatic lipase-
deficient, and human apolipoprotein (apo) A-I transgenic mice by intravenous
infusion of a polyclonal inhibitory anti-mouse-EL antibody resulted in a 25–60 %
increase in HDL-C levels in three mouse models, while triglyceride and non-HDL-
cholesterol levels were not changed (Jin et al. 2003). In human apoA-I transgenic
mice, apoA-I levels were also increased and the HDL phospholipid turnover was
retarded (Jin et al. 2003). Based on this and other studies in mice lacking EL
activity, as well as on studies in humans expressing loss-of-function EL variants,
the inhibition of EL in humans would be expected to raise plasma HDL-C levels
(Brown et al. 2009; Ishida et al. 2003; Ma et al. 2003; Edmondson et al. 2009).
Although the effect of EL inhibition in the reduction of atherosclerotic cardiovas-
cular disease risk has not been proven (Yasuda et al. 2010; Annema and Tietge
2011), EL remains a potential target for pharmacological inhibition, possibly by
antibodies against EL, as a novel strategy to raise HDL-C and reduce the risk of
cardiovascular disease.
3.3 Effect of Antibodies Used for the Treatment of Chronic
Inflammatory Diseases on HDL Antiatherogenic Functions
Patients with chronic inflammatory rheumatic diseases, such as rheumatoid arthritis
and systemic lupus erythematosus, have increased risk for cardiovascular disease
morbidity and mortality (Onat and Direskeneli 2012; Farragher and Bruce 2006;
Popa et al. 2012). Various studies have shown that during the course of these
chronic inflammatory conditions, the levels as well as the antiatherogenic
properties of HDL are affected (Onat and Direskeneli 2012; Popa et al. 2012).
Specifically, patients with rheumatoid arthritis and systemic lupus erythematosus
were found to have proinflammatory HDL (McMahon et al. 2006; Charles-
Schoeman et al. 2009). In addition, cholesterol efflux capacity of HDL was
impaired in rheumatoid arthritis patients with high disease activity and was
correlated with systemic inflammation and HDL’s antioxidant capacity (Charles-
Schoeman et al. 2012). Recommendations for the treatment of rheumatic diseases
propose a tight control of the inflammatory process which probably will favorably
impact the risk of cardiovascular disease. New therapeutics include antibodies
designed to block inflammatory proteins or cells that are produced in abundance
during the disease, such as TNF-α, IL-6, or B cells (Onat and Direskeneli 2012;
Popa et al. 2012). Anti-TNF therapy of rheumatoid arthritis patients with monoclo-
nal antibody infliximab was shown to increase plasma paraoxonase-1 activity and
to improve HDL antioxidative capacity, an effect that was sustained 6 months after
anti-TNF therapy has been initiated (Popa et al. 2009). In addition, another recent
study in rheumatoid arthritis patients treated with rituximab, a B cell depleting
monoclonal antibody against the protein CD20, which is primarily found on the
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surface of B lymphocytes, showed beneficial changes in HDL composition
(Raterman et al. 2013). Specifically, during 6 months of treatment with rituximab,
HDL-associated serum amyloid A decreased in patients with good response to the
therapy, rendering HDL from proatherogenic to less proatherogenic (Raterman
et al. 2013). Future large-scale studies are needed to establish the value of monitor-
ing HDL function during antibody therapy, as well as the impact of this therapy on
cardiovascular disease risk of rheumatic disease patients and possibly other patients
with coronary artery disease who remain at high vascular risk despite contemporary
prevention strategies.
3.4 Vaccines Against Atherosclerosis
A large body of evidence has shown that atherosclerosis is a multifactorial, multi-
phase disease characterized by chronic inflammation and altered immune response.
Therefore, approaches of active immunization have been developed to modulate
atherosclerosis with promising results in preclinical studies. Many studies have
reported reduced atherosclerosis in animal models after immunization using as
antigens LDL (native or modified), apoB100 peptides, heat shock proteins, and
other proteins or phospholipids associated with the initiation and progression of the
atherosclerotic plaque.
Immunization with homologous LDL, oxLDL (copper-oxidized LDL), or
MDA-LDL (LDL modified by malondialdehyde (MDA), an epitope of oxLDL)
generated high titers of antibodies and reduced atherogenesis development in
hypercholesterolemic rabbits, LDLR-deficient rabbits, or apoE-deficient mice
(Palinski et al. 1995; Ameli et al. 1996; George et al. 1998; Zhou et al. 2001).
Similar results were achieved using homologous plaque homogenates (containing
immunogen(s) sharing epitopes on MDA-LDL, MDA-VLDL, and oxidized
cardiolipin) as the antigen (Zhou et al. 2001). The generation of antibodies against
oxidation epitopes in LDL has been proposed to inhibit the binding and uptake of
oxLDL by macrophage scavenger receptors CD36 and SR-BI and therefore to
reduce the formation of foam cells (Steinberg and Witztum 2010). In addition,
induction of oral tolerance to oxLDL can induce a significant increase in CD4
+CD25+Foxp3+ Tregs in spleen and mesenteric lymph nodes, and these cells
specifically respond to oxLDL with increased TGF-β production and significant
attenuation of the initiation and progression of atherogenesis in LDLR-deficient
mice (van Puijvelde et al. 2006). However, since atherosclerosis immune responses
can been triggered against autoantigens, such as anti-oxLDL, all the efforts toward
the development of a successful vaccine against oxLDL should result in the
restoration of tolerance against autoantibodies and balance of pro- and
antiatherogenic immune responses (Samson et al. 2012).
Screening of a library of 302 polypeptides covering the complete sequence of
apoB-100, the major protein component in LDL, in their native state and after MDA
modification, using pooled plasma derived from healthy control subjects, resulted
in the identification of more than 100 different human antibodies reacting against
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MDA-modified apoB100 sequences (Fredrikson et al. 2003a). Immunization with
apoB100 peptide sequences, against which high levels of IgG and IgM antibodies
are present in healthy human controls, was found to reduce atherosclerosis in apoE-
deficient mice by about 60 % (Fredrikson et al. 2003b). Studies on the mechanisms
underlying active immunization using a specific apoB100-related peptide, namely,
the p210, indicated that the atheroprotective effect of immunization with this
peptide is mediated via the activation of CD8+T cells (Chyu et al. 2012) and
CD4+ CD25+Foxp3+ Tregs (Wigren et al. 2011).
Other approaches to reduce atherosclerosis involve the immunization with
antigens other than LDL or apoB100-related peptides. Immunization of hypercho-
lesterolemic rabbits with protein-free liposomes containing dimyristoyl phosphati-
dylcholine, dimyristoyl phosphatidylglycerol, cholesterol (71 %), and lipid A from
Salmonella Minnesota R595 as adjuvant induced the generation of anticholesterol
antibodies and reduced the diet-induced hypercholesterolemia and plaque forma-
tion (Alving et al. 1996). In another study, pneumococcal vaccination was also
found to decrease the atherosclerotic lesion formation (Binder et al. 2003). The use
of Streptococcus pneumoniae as an antigen was based on the finding that during the
progression of atherosclerosis in apoE-deficient mice, autoantibodies against
epitopes of oxLDL, and more specifically against the oxidized phospholipids,
share complete genetic and structural identity with antibodies from the classic
anti-phosphorylcholine B cell clone, T15, which protect against common infectious
pathogens, including pneumococci (Shaw et al. 2000). The reduction of atheroscle-
rosis in LDLR-deficient mice after immunization with S. pneumoniae suggested
molecular mimicry between epitopes of oxLDL and S. pneumonia (Binder
et al. 2003). In another recent study, it was found that T cell hybridomas from
oxLDL-immunized human apoB100 transgenic mice responded against native LDL
and purified apoB100, but not against oxLDL and expressed a single T cell receptor
variable beta chain, TRBV31. Immunization of double human apoB100 transgenic
and LDLR-deficient mice with a TRBV31-derived peptide generated anti-TRBV31
antibodies that blocked T cell recognition of apoB100 and reduced atherosclerosis
(Hermansson et al. 2010).
In the last decade, various therapeutic approaches for reducing atherosclerosis
by immunization were based on heat shock proteins (HSPs). HSPs, which are
named according to their molecular weight, are a highly conserved group of
proteins that have been implicated in atherogenesis (Kilic and Mandal 2012;
Grundtman et al. 2011). Intracellularly, HSPs act as molecular chaperones and
assist in the folding of misfolded proteins, but extracellularly, HSPs can promote
immune responses. Immunization of rabbit or mouse atherosclerotic models with
HSP65 resulted in conflicting results, with some studies showing induction of
atherosclerotic lesions (Xu et al. 1992; George et al. 1999; Zhang et al. 2012d)
and others reduction of atherosclerosis (Maron et al. 2002; Harats et al. 2002; Long
et al. 2012; Klingenberg et al. 2012). Vaccination of high-cholesterol-fed athero-
sclerotic rabbits with a recombinant HSP65-CETP fusion protein resulted in pro-
duction of more protective IL-10 and less adverse IFN-γ, reduction of total
cholesterol and LDL-C levels, as well as decrease of the area of aortic lesions
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(Jun et al. 2012). In addition, the immunization of apoE-deficient or double
apoB48- and LDLR-deficient mice with chimeric proteins containing apoB-100
and/or hHSP60 peptides resulted in the reduction of atherosclerotic lesions
(Li et al. 2011; Lu et al. 2010).
Another target for the treatment of atherosclerosis by immunization involves a
specific cell population, the vascular endothelial growth factor receptor 2
(VEGFR2)-overexpressing cells. Highly VEGFR2 expressing cells include
proliferating endothelial cells that are involved in angiogenesis, a process that
may be associated with the initiation and progression of atherosclerosis (Shi
et al. 1998; Li et al. 2002; Moulton et al. 2003). Vaccination of apoE- or LDLR-
deficient mice against VEGFR2 by an orally administered DNA vaccine, compris-
ing a plasmid encoding murine VEGFR2 carried by live attenuated Salmonella
typhimurium, resulted in a marked induction of CD8+ cytotoxic T cells specific for
VEGFR2 and attenuated the initiation and progression of atherosclerosis (Hauer
et al. 2007). Oral administration of another DNA vaccine, one against CD99, a
membrane protein expressed on vascular endothelium overlying atherosclerotic
plaques, also generated antigen-specific cytotoxic CD8+ T cells and reduced
atherosclerosis in LDLR-deficient mice (van Wanrooij et al. 2008).
In a recent study of a potential treatment option for atherosclerosis, immuniza-
tion of apoE-deficient mice with a virus-like particle-based vaccine against IL-1α,
a cytokine exerting proinflammatory functions and implicated in the development
of atherosclerosis (Kamari et al. 2007), reduced both the inflammatory reaction in
the plaque and plaque progression (Tissot et al. 2013). A current Phase 3 clinical
study that aims to test the inflammatory hypothesis of atherothrombosis has been
designed to evaluate whether Canakinumab can reduce rates of recurrent MI,
stroke, and cardiovascular death among stable patients with coronary artery disease
who remain at high vascular risk due to persistent elevations of high-sensitivity
C-reactive protein (CRP) (>2 mg/L) despite contemporary secondary prevention
strategies (Ridker et al. 2011). Canakinumab is a human monoclonal antibody that
selectively neutralizes IL-1β, a cytokine that exerts proinflammatory effects and has
been implicated in the pathogenesis of atherothrombosis (Fearon and Fearon 2008).
The study which is named Canakinumab Anti-inflammatory Thrombosis Outcomes
Study (CANTOS, ClinicalTrials.gov Identifier: NCT01327846) will randomly
allocate 17,200 patients to either placebo or to Canakinumab at doses of 50, 150,
or 300 mg every 3 months, administered subcutaneously, and all participants will be
followed up over an estimated period of up to 4 years (Ridker et al. 2011). As part of
the CANTOS study, a multinational Phase IIb randomized, placebo-controlled trial
was conducted to evaluate the effects of Canakinumab agent on hemoglobin A1c,
glucose, lipids, CRP, IL-6, and fibrinogen among 556 men and women with
diabetes mellitus and high cardiovascular risk (Ridker et al. 2012). The patients
were randomly allocated to subcutaneous placebo or to subcutaneous Canakinumab
at doses of 5, 15, 50, or 150 mg monthly and followed over 4 months. No effects
were seen for hemoglobin A1c, glucose, insulin, LDL-C, HDL-C, or non-HDL-
cholesterol levels. By contrast, there were significant reductions in CRP, IL-6, and
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fibrinogen levels in both women and men. The CANTOS Investigative Group
members support that these data provide a strong basis for the use of Canakinumab
in humans as an approach to test whether therapeutic targeting of inflammation can
reduce the risk of recurrent events in patients on current standard of care treatment
after MI (Ridker et al. 2012).
Conclusions
Antisense oligonucleotide or gene therapy has been discussed for more than
30 years. The approval for commercial use of the first antisense oligonucleotide
in 1998 by the FDA has catalyzed the development of these types of therapy for
several diseases. Moreover, recent approvals of mipomersen or the gene therapy
drug Glyvera have opened avenues for the use of these novel therapeutic
approaches to treat lipid metabolism disorders. While miRNA and mAbs therapy
to treat dyslipidemia have benefitted from previous existing technology, the
recent clinical trials to target miR-122 through anti-miR technology and to target
PCSK9 through mAbs technology will probably encourage the development of
novel therapies to modulate HDL metabolism and function. mAbs are currently
being investigated for their capacity to decrease LDL-C levels, increase HDL-C
levels, and reduce the risk of cardiovascular events in clinical studies. Initial
studies showed that these compounds are generally safe and well tolerated.
Ongoing, large clinical studies will assess the long-term safety as well as the
efficacy of these new antibody-based drugs in a wide range of dyslipidemic and
cardiovascular disease patients. Even though the complex biological structure
and functions of HDL are probably delaying the benefits of having a drug using
any of these technologies in clinical care, ongoing preclinical or clinical studies
using antisense oligonucleotides, miRNAs, or mAbs envision a bright future for
the HDL field.
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